Together, these data suggested ATO induced degradation of Cyclin D1 and functional suppression of CDK4/6 pathway sensitized OSCC and ESCC to checkpoint inhibitor treatment. This evidence concerns the gene CDK4 and esophageal squamous cell carcinoma.